*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>MMAE (Methionine-Valine-Citrulline-Monomethyl Auristatin E) is a potent <strong>cytotoxic agent</strong> derived from dolastatin 10. Synthesized via <strong>solid-phase peptide synthesis</strong>, it serves as the payload in Antibody-Drug Conjugates (ADCs). Its molecular formula is C<sub>28</sub>H<sub>46</sub>N<sub>4</sub>O<sub>5</sub> with CAS No. 205927-10-2.</p>
<h3>Application</h3>
<ul>
<li><strong>Oncology Therapeutics:</strong> Used as the active linker-payload in ADCs targeting CD30 and Nectin-4 for treating lymphomas and solid tumors.</li>
<li><strong>Pharmaceutical R&D:</strong> Employed in preclinical studies to evaluate drug potency and internalization efficiency of novel antibody conjugates.</li>
<li><strong>Bioconjugation Chemistry:</strong> Serves as a standard reference for optimizing cleavable linkers in targeted delivery systems.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly handled as a <strong>highly potent cytotoxin</strong> requiring specialized containment. Storage must be at -20°C under inert atmosphere. Direct exposure poses severe risks to personnel, necessitating full PPE and engineering controls during manufacturing.</p>